Ion channels have long been drug targets for various diseases, such as pain, seizures, cardiac arrhythmia, and cystic fibrosis. It is estimated that about 15% of approved drugs target ion channels. However, identifying small molecule modulators targeting specific ion channels is challenging and requires carefully constructed screening and validation methods. The increasingly widespread use of high-throughput automated electrophysiology platforms and improved instrumentation to perform patch clamp assays has facilitated more robust ion channel screening paradigms. CROs like Charles River have invested in developing specialty expertise in ion channel screening assay using these high-throughput automated platforms.
Tell Us More About Your Target/Study »
Our discovery services portfolio offers the broadest selection of ion channel and epithelial current assays, with industry-leading expertise to match and backed by laboratories equipped with state-of-the-art equipment utilizing a range of automated patch clamp instruments together with conventional electrophysiology. Our discovery teams have worked across a range of different channel types in cardiovascular, CNS, and rare diseases. We also offer profiling services and cell lines, which are validated for testing at each stage of the drug discovery process, and our experts are ready to work with you to design the right assay and interpret the results.